← Back to Company DatabaseVisit Website
Adaptive Biotechnologies
Immune-driven medicine using adaptive immune system sequencing.
PublicSeattle, WAFounded 2009
About
Adaptive Biotechnologies uses its proprietary immunosequencing platform to profile T-cell and B-cell receptors for cancer diagnostics and drug discovery. Its clonoSEQ test is FDA-cleared for monitoring minimal residual disease in blood cancers. The company partners with Microsoft to leverage AI for mapping the immune response to cancer and other diseases.
Total Funding
$500MKey Product
clonoSEQ minimal residual disease testGeography
North AmericaKey Investors
Madrona VenturesViking Global InvestorsCasdin Capital
Focus Areas
DiagnosticsDrug DiscoveryAI / Machine Learning
Technology
Genomics / SequencingAI / Machine LearningImmunotherapy
Cancer Types
Blood CancersPan-cancer
Last updated: Feb 4, 2026